SHANGHAI, April 01, 2025 (GLOBE NEWSWIRE) -- EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies and T-cell engagers, is pleased to announce the company will be presenting four poster presentations at the upcoming 2025 American Association for Cancer Research (AACR) Annual Meeting taking place in Chicago, Illinois, from April 25-30, 2025, at the McCormick Place Convention Center.

The posters will feature: 1) Clinical results for EMB-01, an EGFR x cMet bispecific antibody, in colorectal cancer; 2) Preclinical data for EM1031, a novel KLK2 x CD3 bispecific T-cell engager; 3) Preclinical data for a novel LY6G6D x CD3 bispecific T-cell engager and 4) Preclinical data for a novel TCR based bispecific platform.

Details for the presentations are as follows:

EMB-01 EGFR x cMet bispecific antibody

  • Title: EMB-01, an EGFR/cMET bispecific antibody, in metastatic colorectal cancer: Results from an International Phase Ib/II study
  • Presentation number: CT168
  • Presentation Date: Tuesday, April 29, 2025
  • Presentation Time: 9:00AM - 12:00PM, local time (Location: Poster Section 49 Board Number 8)
EM1031 KLK2 x CD3 bispecific T-cell engager

Get the latest news
delivered to your inbox
Sign up for The Manila Times newsletters
By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy.

  • Title: EM1031, a novel KLK2 x CD3 bispecific T-cell engager with highly effective efficacy in preclinical models
  • Presentation number: 3520
  • Presentation Date: Monday, April 28, 2025
  • Presentation Time: 2:00PM - 5:00PM, local time (Location: Poster Section 38 Board Number 28)
LY6G6D x CD3 bispecific T-cell engager

  • Title: A novel LY6G6D x CD3 bispecific T-cell engager demonstrates better tumor killing and minimal cytokine release than a benchmark molecule
  • Presentation number: 7317
  • Presentation Date: Wednesday, April 30, 2025
  • Presentation Time: 9:00AM - 12:00PM, local time (Location: Poster Section 40 Board Number 3)
TCR based bispecific platform

  • Title: Development of a novel TCR based bispecific platform for cancer therapy
  • Presentation number: 5446
  • Presentation Date: Tuesday, April 29, 2025
  • Presentation Time: 2:00PM - 5:00PM, local time (Location: Poster Section 15 Board Number 4)
"We are very pleased to share the promising efficacy signal of EMB-01 in Phase Ib/II clinical study for colorectal cancer as a poster presentation at the AACR Annual Meeting, and 3 preclinical TCE assets and platform with differentiated efficacy and safety profile in solid tumors,” said Dr. Chengbin Wu, Founder and CEO of EpimAb. "The results of these studies are also providing validation of our TCE & bispecific technology platform in solid tumors, and we will further leverage this expertise to advance novel therapies for diseases with significant unmet need.”

About EpimAb Biotherapeutics, Inc 

EpimAb Biotherapeutics is a clinical-stage biopharmaceutical company specializing in the development of multi-specific antibodies. Utilizing a broad range of in-house research and technology capabilities, including the proprietary FIT-Ig® (Fabs-In-Tandem Immunoglobulin) and MAT-Fab (Monovalent Asymmetric Tandem Fab) bispecific platform, EpimAb is generating and globally advancing a unique pipeline of transformative preclinical and clinical assets that aim to benefit cancer patients. For further information, please visit: www.epimab.com 

Investor Contact

Dr. David Gu

Phone: +86-21-61951011

Email: IR@epimab.com

BD Contact

Dr. Jason Tang

Phone: +86-21-61951014

Email: partnering@epimab.com